Skip to main content
SpringerLink
Log in

Die zytoreduktive Tumornephrektomie – ein Auslaufmodell?

Cytoreductive nephrectomy for metastatic renal cell carcinoma – obsolete?

  • Journal Club
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Méjean A, Ravaud A, Thezenas S et al (2018) Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 379(5):417–427

    Article  Google Scholar 

  2. Bex A, Albiges L, Ljungberg B et al (2018) Updated European Association of Urology guidelines for cytoreductive nephrectomy in patients with synchronous metastatic clear-cell renal cell carcinoma. Eur Urol. https://doi.org/10.1016/j.eururo.2018.08.008

    Article  PubMed  Google Scholar 

  3. Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277–1290

    Article  CAS  Google Scholar 

  4. Motzer RJ, Penkov K, Haanen JBAG et al (2018) JAVELIN Renal 101: a randomized, phase 3 study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). Ann Oncol 29(Suppl. 8):mdy424.036

    Google Scholar 

  5. https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-in-Combination-with-Pfizers-Inlyta-axitinib-Significantly-Improved-Overall-Survival-OS-and-Progression-free-Survival-PFS-as-First-Line-Therapy-for-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspx. Zugegriffen: 03.12.2018

  6. Rini BI, Tannir NM, Escudier B et al (2018) Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214. Ann Oncol 29(Suppl. 8):mdy283.084

    Google Scholar 

  7. Flanigan RC, Mickisch G, Sylvester R et al (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171(3):1071–1076

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologische Klinik und Poliklinik, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Deutschland

    Marc-Oliver Grimm

Authors
  1. Marc-Oliver Grimm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc-Oliver Grimm.

Ethics declarations

Interessenkonflikt

M.‑O. Grimm ist als Referent und Berater für folgende Firmen tätig gewesen: AstraZeneca, Bayer Health Care, Bristol-Myers Squibb, GlaxoSmithKline, Ipsen, MSD, Novartis, Ono Pharma, Pfizer; Forschungsunterstützung wurde von Novartis und Bristol-Myers Squibb gewährt.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grimm, MO. Die zytoreduktive Tumornephrektomie – ein Auslaufmodell?. Urologe 58, 51–52 (2019). https://doi.org/10.1007/s00120-018-0820-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-018-0820-2

Search

Navigation